Search
forResearch 10 of 1000+
- Hair Care Cosmetics Regulation in Different Countries – A Comparative Study
- Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review
- Cosmetics
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
- Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- In vivo experimental studies for hair growth: systematic review
- Table 1_A decade of hair-loss clinical trials: a registry-based analysis of studies registered on ClinicalTrials.gov.docx
- Current Concepts and Translational Uses of Platelet Rich Plasma Biotechnology
- Electron beam tomography quantitation of coronary calcium and assessment for ischemic coronary disease: a complement to stress testing
- Healthy Skin for Women: A Review of Common Conditions and Therapies
Community 10 of 75
- Just FYI, Here are pictures of 6 months results on Clascoterone 5%. Is it remarkable? No. But it seems likely to be FDA approved considering 1% is already available. This is a win, especially if you pair it with other treatments like Finasteride.
- New warning by FDA on topical finasteride
- Dutasteride would have been approved for AGA by the US FDA.
- Finasteride alternative close to fda approval in the US
- Peeps who arent able to get gains even after using fda approved meds
- Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
- FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
- There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
- Good news for stem cells hair therapies - US federal judge: using patients' stem cells does NOT fall under FDA jurisdiction
- US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
Learn
— no results
Try a deeper search in learn →